
CHRO
Healthcare · Biotechnology · $8.9M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 3 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 13, 2024 | After the close | -2.30 | -2.90 | -26.1% |
| Aug 13, 2024 | After the close | -2.90 | -3.10 | -6.9% |
| May 29, 2024 | Time not confirmed | — | -0.44 | — |
Channel Therapeutics Corporation, a clinical-stage biotech company, develops and commercializes new therapeutics to alleviate pain. It targets sodium ion-channel NaV1.7; and develops NaV blockers that target the body's peripheral nervous system. The company's lead compound is CC8464, which has completed Phase 1 clinical trials for the treatment of moderate-to-severe pain in erythromelalgia and idiopathic small…